IcoSema vs Insulin glargine (Basaglar)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

IcoSema · Kyinsu

Marketed by Novo Nordisk

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05352815 · Phase 3 · completed

Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.

Reported efficacy

Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to week 40): (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001) (met)

Result source: NCT06269107

Insulin glargine (Basaglar)

Marketed by Eli Lilly and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT01421459 · Phase 3 · completed

The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)

Result source: NCT03338010

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIcoSemaInsulin glargine (Basaglar)
HbA1c, change-1.6% vs -0.9%vs Insulin Icodecwk 52 · n 598NCT05352815
2 other results
  • -1.4% vs -0.9% wk 52 · n 325 · Phase 3 · primary NCT05259033
  • -1.5% vs -1.4% wk 52 · Phase 3 · primary NCT05013229
-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459
Body weight, change (kg)-3.7 vs 2.0vs Insulin Icodecwk 52 · n 606NCT05352815
1 other result
  • 0.9 vs -3.8 wk 52 · n 325 · Phase 3 · secondary NCT05259033
1.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459
HbA1c below 7%—Not posted · NCT0501322943.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010
Fasting plasma glucose, change-1.9 vs -1.6vs Insulin Icodecwk 52 · n 552NCT05352815
1 other result
  • -2.7 vs -1.4 wk 52 · n 313 · Phase 3 · secondary NCT05259033
—Not reported
3-point MACE (% with event)—Not posted · NCT05013229—Not reported

HbA1c, change

IcoSema
-1.6% vs -0.9%vs Insulin Icodecwk 52 · n 598NCT05352815
2 other results
  • -1.4% vs -0.9% wk 52 · n 325 · Phase 3 · primary NCT05259033
  • -1.5% vs -1.4% wk 52 · Phase 3 · primary NCT05013229
Insulin glargine (Basaglar)
-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459

Body weight, change (kg)

IcoSema
-3.7 vs 2.0vs Insulin Icodecwk 52 · n 606NCT05352815
1 other result
  • 0.9 vs -3.8 wk 52 · n 325 · Phase 3 · secondary NCT05259033
Insulin glargine (Basaglar)
1.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459

HbA1c below 7%

IcoSema
—Not posted · NCT05013229
Insulin glargine (Basaglar)
43.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010

Fasting plasma glucose, change

IcoSema
-1.9 vs -1.6vs Insulin Icodecwk 52 · n 552NCT05352815
1 other result
  • -2.7 vs -1.4 wk 52 · n 313 · Phase 3 · secondary NCT05259033
Insulin glargine (Basaglar)
—Not reported

3-point MACE (% with event)

IcoSema
—Not posted · NCT05013229
Insulin glargine (Basaglar)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. IcoSema: 3 of 4 rows · Insulin glargine (Basaglar): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIcoSemaInsulin glargine (Basaglar)
Dropout rate
5.4%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
3.8%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
11.9%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
7.6%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.4%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.3%
NCT04153981 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
—
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
—
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.6%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
0.4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT04153981 · Phase 4 · registry result, not featured evidence
Serious AEs
9.2%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
11.1%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
4%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
nausea 23.8%
diarrhoea 15.8%
vomiting 10.6%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
covid-19 15%
nausea 11.7%
diarrhoea 11.1%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
a
nasopharyngitis 5.6%
upper respiratory tract infection 5.1%
abnormal weight gain 2.7%
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
nasopharyngitis 7.2%
upper respiratory tract infection 4%
weight increased 3.2%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
upper respiratory tract infection 20.3%
hypertension 5.6%
injection site pain 4.2%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
anaemia 1.9%
cough 0.4%
hyperglycaemia 0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

IcoSema

Time in Range 75.9% (n=481) vs 61.9% (n=488) Insulin Icodec @ 52wk
absolute value · percentage points
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below Range 0.27 vs 0.33 Insulin Icodec % of time @ 52wk
absolute value · % of time
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Above Range 23.2 vs 36.7 Insulin Icodec % of time @ 52wk
absolute value · % of time
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Fasting Plasma Glucose -1.9 vs -1.65 Insulin Icodec mmol/L @ 52wk
absolute change · mmol/L
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
-2.74 vs -1.41 Semaglutide mmol/L @ 52wk
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 2 or 3 15 vs 13 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 2 15 vs 13 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 3 0 vs 0 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3

Insulin glargine (Basaglar)

HbA1c Less Than 7% 43.7% (n=334) vs 44.9% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than or Equal to 6.5 23.4% (n=334) vs 16.5% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Weight -0.5 kg @ 24wk
absolute change · kg
No placebo or comparator arm
NCT04153981 · Phase 4 · registry result, not featured evidence
HbA1c -0.641% (n=259) @ 12wk
absolute change · percentage points
No placebo or comparator arm
NCT04153981 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.86% (n=259) @ 24wk
NCT04153981 · Phase 4 · registry result, not featured evidence
SMBG 7-point Change mg/dL -38.7 mg @ 24wk
absolute change · mg
No placebo or comparator arm
Blood glucose concentration before breakfast
NCT04153981 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IcoSema's landscape · Insulin glargine (Basaglar)'s landscape